nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CHRM3—ureter—urinary bladder cancer	0.091	0.345	CbGeAlD
Solifenacin—CHRM3—muscle of abdomen—urinary bladder cancer	0.0655	0.249	CbGeAlD
Solifenacin—CYP3A4—urine—urinary bladder cancer	0.0163	0.0617	CbGeAlD
Solifenacin—CHRM5—epithelium—urinary bladder cancer	0.014	0.0529	CbGeAlD
Solifenacin—CHRM2—prostate gland—urinary bladder cancer	0.013	0.0495	CbGeAlD
Solifenacin—Benazepril—MTHFR—urinary bladder cancer	0.0126	1	CrCbGaD
Solifenacin—CHRM1—prostate gland—urinary bladder cancer	0.0119	0.045	CbGeAlD
Solifenacin—CHRM3—prostate gland—urinary bladder cancer	0.0106	0.0403	CbGeAlD
Solifenacin—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00752	0.0285	CbGeAlD
Solifenacin—CHRM3—renal system—urinary bladder cancer	0.00724	0.0275	CbGeAlD
Solifenacin—CHRM3—urethra—urinary bladder cancer	0.00711	0.027	CbGeAlD
Solifenacin—CHRM1—female reproductive system—urinary bladder cancer	0.00648	0.0246	CbGeAlD
Solifenacin—CHRM3—female reproductive system—urinary bladder cancer	0.0058	0.022	CbGeAlD
Solifenacin—CYP3A4—renal system—urinary bladder cancer	0.00398	0.0151	CbGeAlD
Solifenacin—CYP3A4—female reproductive system—urinary bladder cancer	0.00319	0.0121	CbGeAlD
Solifenacin—Constipation—Thiotepa—urinary bladder cancer	0.00156	0.00215	CcSEcCtD
Solifenacin—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00153	0.00212	CcSEcCtD
Solifenacin—Infection—Gemcitabine—urinary bladder cancer	0.00152	0.0021	CcSEcCtD
Solifenacin—Confusional state—Fluorouracil—urinary bladder cancer	0.00152	0.0021	CcSEcCtD
Solifenacin—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00151	0.00208	CcSEcCtD
Solifenacin—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.0015	0.00208	CcSEcCtD
Solifenacin—Feeling abnormal—Thiotepa—urinary bladder cancer	0.0015	0.00207	CcSEcCtD
Solifenacin—Infection—Fluorouracil—urinary bladder cancer	0.0015	0.00207	CcSEcCtD
Solifenacin—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00149	0.00206	CcSEcCtD
Solifenacin—Skin disorder—Gemcitabine—urinary bladder cancer	0.00149	0.00206	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00148	0.00205	CcSEcCtD
Solifenacin—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00148	0.00204	CcSEcCtD
Solifenacin—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.00147	0.00203	CcSEcCtD
Solifenacin—Tachycardia—Fluorouracil—urinary bladder cancer	0.00147	0.00203	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.00146	0.00202	CcSEcCtD
Solifenacin—Renal impairment—Doxorubicin—urinary bladder cancer	0.00145	0.00201	CcSEcCtD
Solifenacin—Urticaria—Thiotepa—urinary bladder cancer	0.00145	0.002	CcSEcCtD
Solifenacin—Abdominal pain—Thiotepa—urinary bladder cancer	0.00144	0.00199	CcSEcCtD
Solifenacin—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00143	0.00197	CcSEcCtD
Solifenacin—Infection—Cisplatin—urinary bladder cancer	0.00142	0.00196	CcSEcCtD
Solifenacin—Nervous system disorder—Cisplatin—urinary bladder cancer	0.0014	0.00194	CcSEcCtD
Solifenacin—Cough—Etoposide—urinary bladder cancer	0.0014	0.00193	CcSEcCtD
Solifenacin—Tachycardia—Cisplatin—urinary bladder cancer	0.00139	0.00193	CcSEcCtD
Solifenacin—Skin disorder—Cisplatin—urinary bladder cancer	0.00139	0.00192	CcSEcCtD
Solifenacin—Hypertension—Etoposide—urinary bladder cancer	0.00138	0.00191	CcSEcCtD
Solifenacin—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.00138	0.0019	CcSEcCtD
Solifenacin—Dry skin—Epirubicin—urinary bladder cancer	0.00137	0.00189	CcSEcCtD
Solifenacin—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.00136	0.00188	CcSEcCtD
Solifenacin—Somnolence—Gemcitabine—urinary bladder cancer	0.00136	0.00188	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00136	0.00187	CcSEcCtD
Solifenacin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00134	0.00185	CcSEcCtD
Solifenacin—Somnolence—Fluorouracil—urinary bladder cancer	0.00134	0.00185	CcSEcCtD
Solifenacin—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00133	0.00184	CcSEcCtD
Solifenacin—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00133	0.00183	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00132	0.00183	CcSEcCtD
Solifenacin—Fatigue—Gemcitabine—urinary bladder cancer	0.00132	0.00183	CcSEcCtD
Solifenacin—Confusional state—Etoposide—urinary bladder cancer	0.00132	0.00182	CcSEcCtD
Solifenacin—Muscular weakness—Epirubicin—urinary bladder cancer	0.00132	0.00182	CcSEcCtD
Solifenacin—Constipation—Gemcitabine—urinary bladder cancer	0.00131	0.00181	CcSEcCtD
Solifenacin—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00131	0.00181	CcSEcCtD
Solifenacin—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00131	0.00181	CcSEcCtD
Solifenacin—Asthenia—Thiotepa—urinary bladder cancer	0.00131	0.00181	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.0013	0.0018	CcSEcCtD
Solifenacin—Infection—Etoposide—urinary bladder cancer	0.0013	0.0018	CcSEcCtD
Solifenacin—Influenza—Epirubicin—urinary bladder cancer	0.00129	0.00178	CcSEcCtD
Solifenacin—Dysuria—Methotrexate—urinary bladder cancer	0.00129	0.00178	CcSEcCtD
Solifenacin—Pruritus—Thiotepa—urinary bladder cancer	0.00129	0.00178	CcSEcCtD
Solifenacin—Tachycardia—Etoposide—urinary bladder cancer	0.00128	0.00177	CcSEcCtD
Solifenacin—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.00128	0.00176	CcSEcCtD
Solifenacin—Skin disorder—Etoposide—urinary bladder cancer	0.00127	0.00176	CcSEcCtD
Solifenacin—Dry skin—Doxorubicin—urinary bladder cancer	0.00127	0.00175	CcSEcCtD
Solifenacin—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00126	0.00175	CcSEcCtD
Solifenacin—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.00126	0.00174	CcSEcCtD
Solifenacin—Decreased appetite—Cisplatin—urinary bladder cancer	0.00124	0.00172	CcSEcCtD
Solifenacin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00124	0.00172	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00123	0.0017	CcSEcCtD
Solifenacin—Infestation NOS—Methotrexate—urinary bladder cancer	0.00123	0.0017	CcSEcCtD
Solifenacin—Infestation—Methotrexate—urinary bladder cancer	0.00123	0.0017	CcSEcCtD
Solifenacin—Depression—Methotrexate—urinary bladder cancer	0.00123	0.00169	CcSEcCtD
Solifenacin—Muscular weakness—Doxorubicin—urinary bladder cancer	0.00122	0.00168	CcSEcCtD
Solifenacin—Renal failure—Methotrexate—urinary bladder cancer	0.00121	0.00167	CcSEcCtD
Solifenacin—Dysuria—Epirubicin—urinary bladder cancer	0.00121	0.00167	CcSEcCtD
Solifenacin—Dizziness—Thiotepa—urinary bladder cancer	0.00121	0.00166	CcSEcCtD
Solifenacin—Urticaria—Fluorouracil—urinary bladder cancer	0.0012	0.00165	CcSEcCtD
Solifenacin—Influenza—Doxorubicin—urinary bladder cancer	0.00119	0.00165	CcSEcCtD
Solifenacin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00118	0.00163	CcSEcCtD
Solifenacin—Somnolence—Etoposide—urinary bladder cancer	0.00116	0.00161	CcSEcCtD
Solifenacin—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00116	0.00161	CcSEcCtD
Solifenacin—Vomiting—Thiotepa—urinary bladder cancer	0.00116	0.0016	CcSEcCtD
Solifenacin—Infestation NOS—Epirubicin—urinary bladder cancer	0.00115	0.00159	CcSEcCtD
Solifenacin—Infestation—Epirubicin—urinary bladder cancer	0.00115	0.00159	CcSEcCtD
Solifenacin—Rash—Thiotepa—urinary bladder cancer	0.00115	0.00159	CcSEcCtD
Solifenacin—Dermatitis—Thiotepa—urinary bladder cancer	0.00115	0.00159	CcSEcCtD
Solifenacin—Headache—Thiotepa—urinary bladder cancer	0.00114	0.00158	CcSEcCtD
Solifenacin—Decreased appetite—Etoposide—urinary bladder cancer	0.00114	0.00157	CcSEcCtD
Solifenacin—Renal failure—Epirubicin—urinary bladder cancer	0.00113	0.00156	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00113	0.00156	CcSEcCtD
Solifenacin—Fatigue—Etoposide—urinary bladder cancer	0.00113	0.00156	CcSEcCtD
Solifenacin—Constipation—Etoposide—urinary bladder cancer	0.00112	0.00155	CcSEcCtD
Solifenacin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00112	0.00154	CcSEcCtD
Solifenacin—Dysuria—Doxorubicin—urinary bladder cancer	0.00112	0.00154	CcSEcCtD
Solifenacin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00111	0.00153	CcSEcCtD
Solifenacin—Asthenia—Gemcitabine—urinary bladder cancer	0.0011	0.00152	CcSEcCtD
Solifenacin—Pharyngitis—Methotrexate—urinary bladder cancer	0.0011	0.00151	CcSEcCtD
Solifenacin—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00109	0.00151	CcSEcCtD
Solifenacin—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00109	0.0015	CcSEcCtD
Solifenacin—Pruritus—Gemcitabine—urinary bladder cancer	0.00108	0.0015	CcSEcCtD
Solifenacin—Nausea—Thiotepa—urinary bladder cancer	0.00108	0.0015	CcSEcCtD
Solifenacin—Urethral disorder—Methotrexate—urinary bladder cancer	0.00108	0.00149	CcSEcCtD
Solifenacin—Feeling abnormal—Etoposide—urinary bladder cancer	0.00108	0.00149	CcSEcCtD
Solifenacin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00107	0.00148	CcSEcCtD
Solifenacin—Pruritus—Fluorouracil—urinary bladder cancer	0.00107	0.00147	CcSEcCtD
Solifenacin—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00106	0.00147	CcSEcCtD
Solifenacin—Infestation—Doxorubicin—urinary bladder cancer	0.00106	0.00147	CcSEcCtD
Solifenacin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00105	0.00145	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—urinary bladder cancer	0.00105	0.00145	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00104	0.00144	CcSEcCtD
Solifenacin—Urticaria—Etoposide—urinary bladder cancer	0.00104	0.00144	CcSEcCtD
Solifenacin—Abdominal pain—Etoposide—urinary bladder cancer	0.00103	0.00143	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00103	0.00143	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—urinary bladder cancer	0.00103	0.00142	CcSEcCtD
Solifenacin—Asthenia—Cisplatin—urinary bladder cancer	0.00103	0.00142	CcSEcCtD
Solifenacin—Pharyngitis—Epirubicin—urinary bladder cancer	0.00103	0.00142	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00102	0.00142	CcSEcCtD
Solifenacin—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00102	0.00141	CcSEcCtD
Solifenacin—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00102	0.00141	CcSEcCtD
Solifenacin—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00101	0.0014	CcSEcCtD
Solifenacin—Urethral disorder—Epirubicin—urinary bladder cancer	0.00101	0.0014	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00101	0.00139	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—urinary bladder cancer	0.001	0.00138	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—urinary bladder cancer	0.000997	0.00138	CcSEcCtD
Solifenacin—Dizziness—Fluorouracil—urinary bladder cancer	0.000997	0.00138	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000995	0.00137	CcSEcCtD
Solifenacin—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000977	0.00135	CcSEcCtD
Solifenacin—Vomiting—Gemcitabine—urinary bladder cancer	0.000975	0.00135	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—urinary bladder cancer	0.000967	0.00134	CcSEcCtD
Solifenacin—Rash—Gemcitabine—urinary bladder cancer	0.000967	0.00134	CcSEcCtD
Solifenacin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000966	0.00133	CcSEcCtD
Solifenacin—Eye disorder—Epirubicin—urinary bladder cancer	0.000965	0.00133	CcSEcCtD
Solifenacin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000964	0.00133	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—urinary bladder cancer	0.000961	0.00133	CcSEcCtD
Solifenacin—Headache—Gemcitabine—urinary bladder cancer	0.00096	0.00133	CcSEcCtD
Solifenacin—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000959	0.00132	CcSEcCtD
Solifenacin—Vomiting—Fluorouracil—urinary bladder cancer	0.000958	0.00132	CcSEcCtD
Solifenacin—Rash—Fluorouracil—urinary bladder cancer	0.00095	0.00131	CcSEcCtD
Solifenacin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000949	0.00131	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000948	0.00131	CcSEcCtD
Solifenacin—Headache—Fluorouracil—urinary bladder cancer	0.000944	0.0013	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000944	0.0013	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000941	0.0013	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—urinary bladder cancer	0.000941	0.0013	CcSEcCtD
Solifenacin—Asthenia—Etoposide—urinary bladder cancer	0.000939	0.0013	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000939	0.0013	CcSEcCtD
Solifenacin—Angiopathy—Epirubicin—urinary bladder cancer	0.000937	0.00129	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000937	0.00129	CcSEcCtD
Solifenacin—Immune system disorder—Epirubicin—urinary bladder cancer	0.000933	0.00129	CcSEcCtD
Solifenacin—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000931	0.00129	CcSEcCtD
Solifenacin—Pruritus—Etoposide—urinary bladder cancer	0.000926	0.00128	CcSEcCtD
Solifenacin—Nausea—Gemcitabine—urinary bladder cancer	0.000911	0.00126	CcSEcCtD
Solifenacin—Vomiting—Cisplatin—urinary bladder cancer	0.000908	0.00126	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—urinary bladder cancer	0.000905	0.00125	CcSEcCtD
Solifenacin—Mental disorder—Epirubicin—urinary bladder cancer	0.000905	0.00125	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000904	0.00125	CcSEcCtD
Solifenacin—Rash—Cisplatin—urinary bladder cancer	0.000901	0.00124	CcSEcCtD
Solifenacin—Dermatitis—Cisplatin—urinary bladder cancer	0.0009	0.00124	CcSEcCtD
Solifenacin—Malnutrition—Epirubicin—urinary bladder cancer	0.000899	0.00124	CcSEcCtD
Solifenacin—Nausea—Fluorouracil—urinary bladder cancer	0.000895	0.00124	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—urinary bladder cancer	0.000893	0.00123	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000887	0.00123	CcSEcCtD
Solifenacin—Dysgeusia—Epirubicin—urinary bladder cancer	0.00088	0.00122	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—urinary bladder cancer	0.000867	0.0012	CcSEcCtD
Solifenacin—Dizziness—Etoposide—urinary bladder cancer	0.000866	0.0012	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000863	0.00119	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000861	0.00119	CcSEcCtD
Solifenacin—Nausea—Cisplatin—urinary bladder cancer	0.000849	0.00117	CcSEcCtD
Solifenacin—Vision blurred—Epirubicin—urinary bladder cancer	0.000847	0.00117	CcSEcCtD
Solifenacin—Cough—Methotrexate—urinary bladder cancer	0.000838	0.00116	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—urinary bladder cancer	0.000837	0.00116	CcSEcCtD
Solifenacin—Vomiting—Etoposide—urinary bladder cancer	0.000832	0.00115	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—urinary bladder cancer	0.000832	0.00115	CcSEcCtD
Solifenacin—Rash—Etoposide—urinary bladder cancer	0.000825	0.00114	CcSEcCtD
Solifenacin—Dermatitis—Etoposide—urinary bladder cancer	0.000825	0.00114	CcSEcCtD
Solifenacin—Headache—Etoposide—urinary bladder cancer	0.00082	0.00113	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000815	0.00113	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000812	0.00112	CcSEcCtD
Solifenacin—Palpitations—Epirubicin—urinary bladder cancer	0.000794	0.0011	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—urinary bladder cancer	0.000791	0.00109	CcSEcCtD
Solifenacin—Cough—Epirubicin—urinary bladder cancer	0.000785	0.00108	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000784	0.00108	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—urinary bladder cancer	0.000784	0.00108	CcSEcCtD
Solifenacin—Infection—Methotrexate—urinary bladder cancer	0.000779	0.00108	CcSEcCtD
Solifenacin—Nausea—Etoposide—urinary bladder cancer	0.000778	0.00107	CcSEcCtD
Solifenacin—Hypertension—Epirubicin—urinary bladder cancer	0.000776	0.00107	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000769	0.00106	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—urinary bladder cancer	0.000762	0.00105	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00076	0.00105	CcSEcCtD
Solifenacin—Dry mouth—Epirubicin—urinary bladder cancer	0.000749	0.00103	CcSEcCtD
Solifenacin—Confusional state—Epirubicin—urinary bladder cancer	0.00074	0.00102	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—urinary bladder cancer	0.000735	0.00102	CcSEcCtD
Solifenacin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000734	0.00101	CcSEcCtD
Solifenacin—Infection—Epirubicin—urinary bladder cancer	0.000729	0.00101	CcSEcCtD
Solifenacin—Cough—Doxorubicin—urinary bladder cancer	0.000726	0.001	CcSEcCtD
Solifenacin—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00072	0.000994	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—urinary bladder cancer	0.000718	0.000992	CcSEcCtD
Solifenacin—Tachycardia—Epirubicin—urinary bladder cancer	0.000716	0.000989	CcSEcCtD
Solifenacin—Skin disorder—Epirubicin—urinary bladder cancer	0.000713	0.000985	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000703	0.000972	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—urinary bladder cancer	0.000697	0.000963	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—urinary bladder cancer	0.000693	0.000957	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—urinary bladder cancer	0.00069	0.000954	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—urinary bladder cancer	0.000685	0.000946	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—urinary bladder cancer	0.000682	0.000942	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000679	0.000938	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000677	0.000935	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—urinary bladder cancer	0.000676	0.000934	CcSEcCtD
Solifenacin—Infection—Doxorubicin—urinary bladder cancer	0.000674	0.000932	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000666	0.00092	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—urinary bladder cancer	0.000663	0.000915	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—urinary bladder cancer	0.000659	0.000911	CcSEcCtD
Solifenacin—Somnolence—Epirubicin—urinary bladder cancer	0.000652	0.000901	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000646	0.000893	CcSEcCtD
Solifenacin—Dyspepsia—Epirubicin—urinary bladder cancer	0.000646	0.000892	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000641	0.000886	CcSEcCtD
Solifenacin—Decreased appetite—Epirubicin—urinary bladder cancer	0.000638	0.000881	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000633	0.000875	CcSEcCtD
Solifenacin—Fatigue—Epirubicin—urinary bladder cancer	0.000633	0.000874	CcSEcCtD
Solifenacin—Constipation—Epirubicin—urinary bladder cancer	0.000627	0.000867	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—urinary bladder cancer	0.000623	0.000861	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—urinary bladder cancer	0.00062	0.000856	CcSEcCtD
Solifenacin—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000605	0.000835	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—urinary bladder cancer	0.000604	0.000834	CcSEcCtD
Solifenacin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.0006	0.000829	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000598	0.000826	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00059	0.000815	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000586	0.00081	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—urinary bladder cancer	0.000585	0.000809	CcSEcCtD
Solifenacin—Urticaria—Epirubicin—urinary bladder cancer	0.000583	0.000805	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—urinary bladder cancer	0.000581	0.000802	CcSEcCtD
Solifenacin—Abdominal pain—Epirubicin—urinary bladder cancer	0.00058	0.000801	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000578	0.000798	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—urinary bladder cancer	0.000563	0.000777	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000559	0.000773	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000555	0.000767	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—urinary bladder cancer	0.000555	0.000766	CcSEcCtD
Solifenacin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000541	0.000747	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—urinary bladder cancer	0.000539	0.000745	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000537	0.000741	CcSEcCtD
Solifenacin—Asthenia—Epirubicin—urinary bladder cancer	0.000526	0.000727	CcSEcCtD
Solifenacin—Pruritus—Epirubicin—urinary bladder cancer	0.000519	0.000717	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—urinary bladder cancer	0.000518	0.000716	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.0005	0.000691	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—urinary bladder cancer	0.000499	0.000689	CcSEcCtD
Solifenacin—Rash—Methotrexate—urinary bladder cancer	0.000494	0.000683	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—urinary bladder cancer	0.000494	0.000682	CcSEcCtD
Solifenacin—Headache—Methotrexate—urinary bladder cancer	0.000491	0.000679	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—urinary bladder cancer	0.000487	0.000673	CcSEcCtD
Solifenacin—Dizziness—Epirubicin—urinary bladder cancer	0.000485	0.00067	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—urinary bladder cancer	0.00048	0.000664	CcSEcCtD
Solifenacin—Vomiting—Epirubicin—urinary bladder cancer	0.000467	0.000645	CcSEcCtD
Solifenacin—Nausea—Methotrexate—urinary bladder cancer	0.000466	0.000643	CcSEcCtD
Solifenacin—Rash—Epirubicin—urinary bladder cancer	0.000463	0.000639	CcSEcCtD
Solifenacin—Dermatitis—Epirubicin—urinary bladder cancer	0.000462	0.000639	CcSEcCtD
Solifenacin—Headache—Epirubicin—urinary bladder cancer	0.00046	0.000635	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—urinary bladder cancer	0.000449	0.00062	CcSEcCtD
Solifenacin—Nausea—Epirubicin—urinary bladder cancer	0.000436	0.000602	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—urinary bladder cancer	0.000432	0.000596	CcSEcCtD
Solifenacin—Rash—Doxorubicin—urinary bladder cancer	0.000428	0.000591	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000428	0.000591	CcSEcCtD
Solifenacin—Headache—Doxorubicin—urinary bladder cancer	0.000425	0.000588	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—urinary bladder cancer	0.000403	0.000557	CcSEcCtD
